Related references
Note: Only part of the references are listed.Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response
Carla S. Fisher et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer
Dabei Tang et al.
MEDICAL ONCOLOGY (2012)
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Jiehua He et al.
MEDICAL ONCOLOGY (2012)
Aromatase, breast cancer and obesity: a complex interaction
Serdar E. Bulun et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger
Mia M. Gaudet et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer
Amanda I. Phipps et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Directed Therapy of Subtypes of Triple-Negative Breast Cancer
Lisa A. Carey
ONCOLOGIST (2011)
Commentary: Chemotherapy Dosing in Obese Patients With Cancer-The Need for Evidence-Based Clinical Practice Guidelines
Gary H. Lyman
JOURNAL OF ONCOLOGY PRACTICE (2011)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows et al.
PLOS MEDICINE (2010)
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status
William D. Foulkes et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Time to Disease Recurrence in Basal-Type Breast Cancers Effects of Tumor Size and Lymph Node Status
Rebecca Dent et al.
CANCER (2009)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Breast cancer adjuvant chemotherapy dosing in obese patients - Dissemination of information from clinical trials to clinical practice
Christopher G. Greenman et al.
CANCER (2008)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Marc Tischkowitz et al.
BMC CANCER (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas
SM Rodríguez-Pinilla et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Undertreatment of obese women receiving breast cancer chemotherapy
JJ Griggs et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Breast cancer and obesity: An update
GD Stephenson et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2003)
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
JY Pierga et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
